Chemokine receptors as new molecular targets for antiviral therapy

F. Santoro, L. Vassena, P. Lusso

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Extraordinary advancements have been made over the past decade in our understanding of the molecular mechanism of human immunodeficiency virus (HIV) entry into cells. The external HIV envelope glycoprotein, gp120, sequentially interacts with two cellular receptor molecules, the CD4 glycoprotein and a chemokine receptor, such as CCR5 or CXCR4, leading to the activation of the fusogenic domain of the transmembrane viral glycoprotein, gp41, which changes its conformation to create a hairpin structure that eventually triggers fusion between the viral and cellular membranes. Each of these discrete steps in the viral entry process represents a potetial target for new antiviral agents. Current efforts to develop safe and effective HIV entry inhibitors are focused on naturally occurring proteins (e.g., chemokines, antibodies), engineered or modified derivatives of natural proteins (e.g., multimerized soluble CD4, gp41 - or chemokine - derived synthetic peptides), as well as small synthetic compounds obtained either by high-throughput screening of large compound libraries or by structure-guided rational design. The recent introduction in therapy of the first fusion inhibitor, the gp41-derived synthetic peptide T20, heralds a new era in the treatment of AIDS, which will hopefully lead to more effective multi-drug regimens with reduced adverse effects for the patients.

Original languageEnglish
Pages (from-to)17-29
Number of pages13
JournalNew Microbiologica
Volume27
Issue number2 SUPPL. 1
Publication statusPublished - 2004

Fingerprint

Chemokine Receptors
Antiviral Agents
Virus Internalization
CD4 Antigens
Glycoproteins
HIV
Chemokines
Libraries
Acquired Immunodeficiency Syndrome
Proteins
Therapeutics
Peptides
Membranes
Antibodies
Pharmaceutical Preparations

Keywords

  • Antivirals
  • Chemokines
  • HIV
  • Receptors
  • Viral entry

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Santoro, F., Vassena, L., & Lusso, P. (2004). Chemokine receptors as new molecular targets for antiviral therapy. New Microbiologica, 27(2 SUPPL. 1), 17-29.

Chemokine receptors as new molecular targets for antiviral therapy. / Santoro, F.; Vassena, L.; Lusso, P.

In: New Microbiologica, Vol. 27, No. 2 SUPPL. 1, 2004, p. 17-29.

Research output: Contribution to journalArticle

Santoro, F, Vassena, L & Lusso, P 2004, 'Chemokine receptors as new molecular targets for antiviral therapy', New Microbiologica, vol. 27, no. 2 SUPPL. 1, pp. 17-29.
Santoro F, Vassena L, Lusso P. Chemokine receptors as new molecular targets for antiviral therapy. New Microbiologica. 2004;27(2 SUPPL. 1):17-29.
Santoro, F. ; Vassena, L. ; Lusso, P. / Chemokine receptors as new molecular targets for antiviral therapy. In: New Microbiologica. 2004 ; Vol. 27, No. 2 SUPPL. 1. pp. 17-29.
@article{28d7cfbcd382494f9eba5d89d7c008d5,
title = "Chemokine receptors as new molecular targets for antiviral therapy",
abstract = "Extraordinary advancements have been made over the past decade in our understanding of the molecular mechanism of human immunodeficiency virus (HIV) entry into cells. The external HIV envelope glycoprotein, gp120, sequentially interacts with two cellular receptor molecules, the CD4 glycoprotein and a chemokine receptor, such as CCR5 or CXCR4, leading to the activation of the fusogenic domain of the transmembrane viral glycoprotein, gp41, which changes its conformation to create a hairpin structure that eventually triggers fusion between the viral and cellular membranes. Each of these discrete steps in the viral entry process represents a potetial target for new antiviral agents. Current efforts to develop safe and effective HIV entry inhibitors are focused on naturally occurring proteins (e.g., chemokines, antibodies), engineered or modified derivatives of natural proteins (e.g., multimerized soluble CD4, gp41 - or chemokine - derived synthetic peptides), as well as small synthetic compounds obtained either by high-throughput screening of large compound libraries or by structure-guided rational design. The recent introduction in therapy of the first fusion inhibitor, the gp41-derived synthetic peptide T20, heralds a new era in the treatment of AIDS, which will hopefully lead to more effective multi-drug regimens with reduced adverse effects for the patients.",
keywords = "Antivirals, Chemokines, HIV, Receptors, Viral entry",
author = "F. Santoro and L. Vassena and P. Lusso",
year = "2004",
language = "English",
volume = "27",
pages = "17--29",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Chemokine receptors as new molecular targets for antiviral therapy

AU - Santoro, F.

AU - Vassena, L.

AU - Lusso, P.

PY - 2004

Y1 - 2004

N2 - Extraordinary advancements have been made over the past decade in our understanding of the molecular mechanism of human immunodeficiency virus (HIV) entry into cells. The external HIV envelope glycoprotein, gp120, sequentially interacts with two cellular receptor molecules, the CD4 glycoprotein and a chemokine receptor, such as CCR5 or CXCR4, leading to the activation of the fusogenic domain of the transmembrane viral glycoprotein, gp41, which changes its conformation to create a hairpin structure that eventually triggers fusion between the viral and cellular membranes. Each of these discrete steps in the viral entry process represents a potetial target for new antiviral agents. Current efforts to develop safe and effective HIV entry inhibitors are focused on naturally occurring proteins (e.g., chemokines, antibodies), engineered or modified derivatives of natural proteins (e.g., multimerized soluble CD4, gp41 - or chemokine - derived synthetic peptides), as well as small synthetic compounds obtained either by high-throughput screening of large compound libraries or by structure-guided rational design. The recent introduction in therapy of the first fusion inhibitor, the gp41-derived synthetic peptide T20, heralds a new era in the treatment of AIDS, which will hopefully lead to more effective multi-drug regimens with reduced adverse effects for the patients.

AB - Extraordinary advancements have been made over the past decade in our understanding of the molecular mechanism of human immunodeficiency virus (HIV) entry into cells. The external HIV envelope glycoprotein, gp120, sequentially interacts with two cellular receptor molecules, the CD4 glycoprotein and a chemokine receptor, such as CCR5 or CXCR4, leading to the activation of the fusogenic domain of the transmembrane viral glycoprotein, gp41, which changes its conformation to create a hairpin structure that eventually triggers fusion between the viral and cellular membranes. Each of these discrete steps in the viral entry process represents a potetial target for new antiviral agents. Current efforts to develop safe and effective HIV entry inhibitors are focused on naturally occurring proteins (e.g., chemokines, antibodies), engineered or modified derivatives of natural proteins (e.g., multimerized soluble CD4, gp41 - or chemokine - derived synthetic peptides), as well as small synthetic compounds obtained either by high-throughput screening of large compound libraries or by structure-guided rational design. The recent introduction in therapy of the first fusion inhibitor, the gp41-derived synthetic peptide T20, heralds a new era in the treatment of AIDS, which will hopefully lead to more effective multi-drug regimens with reduced adverse effects for the patients.

KW - Antivirals

KW - Chemokines

KW - HIV

KW - Receptors

KW - Viral entry

UR - http://www.scopus.com/inward/record.url?scp=11844302187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844302187&partnerID=8YFLogxK

M3 - Article

C2 - 15646061

AN - SCOPUS:11844302187

VL - 27

SP - 17

EP - 29

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 2 SUPPL. 1

ER -